Daly Adrian F, Rixhon Martine, Adam Christelle, Dempegioti Anastasia, Tichomirowa Maria A, Beckers Albert
Department of Endocrinology, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman, 4000 Liège, Belgium.
J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75. doi: 10.1210/jc.2006-1668. Epub 2006 Sep 12.
Prevalence data are important for assessing the burden of disease on the health care system; data on pituitary adenoma prevalence are very scarce.
The objective of the study was to measure the prevalence of clinically relevant pituitary adenomas in a well-defined population.
This was a cross-sectional, intensive, case-finding study performed in three regions of the province of Liège, Belgium, to measure pituitary adenoma prevalence as of September 30, 2005.
The study was conducted in specialist and general medical practitioner patient populations, referral hospitals, and investigational centers.
Three demographically and geographically distinct districts of the province of Liège were delineated precisely using postal codes. Medical practitioners in these districts were recruited, and patients with pituitary adenomas under their care were identified. Diagnoses were confirmed after retrieval of clinical, hormonal, radiological, and pathological data; full demographic and therapeutic follow-up data were collected in all cases.
Sixty-eight patients with clinically relevant pituitary adenomas were identified in a population of 71,972 individuals; the mean (+/- sd) prevalence was 94 +/- 19.3 cases per 100,000 population (95% confidence interval, 72.2 to 115.8). The group was 67.6% female and had a mean age at diagnosis of 40.3 yr; 42.6% had macroadenomas and 55.9% underwent surgery. Prolactinomas comprised 66% of the group, with the rest having nonsecreting tumors (14.7%), somatotropinomas (13.2%), or Cushing's disease (5.9%); 20.6% had hypopituitarism.
The prevalence of pituitary adenomas in the study population (one case in 1064 individuals) was more than 3.5-5 times that previously reported. This increased prevalence may have important implications when prioritizing funding for research and treatment of pituitary adenomas.
患病率数据对于评估疾病对医疗保健系统的负担很重要；垂体腺瘤患病率的数据非常稀少。
本研究的目的是测量在一个明确界定的人群中临床相关垂体腺瘤的患病率。
这是一项横断面、密集的病例发现研究，在比利时列日省的三个地区进行，以测量截至2005年9月30日的垂体腺瘤患病率。
该研究在专科医生和全科医生的患者群体、转诊医院和研究中心进行。
使用邮政编码精确划定列日省三个在人口统计学和地理上不同的地区。招募这些地区的医生，并识别他们所照料的垂体腺瘤患者。在检索临床、激素、放射学和病理学数据后确诊；所有病例均收集完整的人口统计学和治疗随访数据。
在71972人的人群中识别出68例临床相关垂体腺瘤患者；平均（±标准差）患病率为每10万人94±19.3例（95%置信区间，72.2至115.8）。该组女性占67.6%，诊断时的平均年龄为40.3岁；42.6%患有大腺瘤，55.9%接受了手术。催乳素瘤占该组的66%，其余为无分泌功能肿瘤（14.7%）、生长激素瘤（13.2%）或库欣病（5.9%）；20.6%有垂体功能减退。
研究人群中垂体腺瘤的患病率（1064人中1例）比先前报告的高出3.5至5倍以上。这种患病率的增加在为垂体腺瘤的研究和治疗确定资金优先顺序时可能具有重要意义。
